Similar articles

• A novel orally active inhibitor of IL-1 generation: synthesis and structure-activity relationships of 3-(4-hydroxy-1-naphthalenyl)-2-propenoic acid derivatives.

  Tanaka M, Chiba K, Okita M, Kaneko T, Tagami K, Hibi S, Okamoto Y, Shirota H, Goto M, Obaishi H, et al. Tanaka M, et al. J Med Chem. 1992 Dec 11;35(25):4665-75. doi: 10.1021/jm00103a003. J Med Chem. 1992. PMID: 1469696
• A novel inhibitor of IL-1 generation, E5090: in vitro inhibitory effects on the generation of IL-1 by human monocytes.

  Goto M, Chiba K, Hashida R, Shirota H. Goto M, et al. Agents Actions Suppl. 1991;32:225-9. doi: 10.1007/978-3-0348-7405-2_30. Agents Actions Suppl. 1991. PMID: 2069091
• Antiinflammatory properties of E5090, a novel orally active inhibitor of IL-1 generation.

  Shirota H, Chiba K, Goto M, Hashida R, Ono H. Shirota H, et al. Agents Actions Suppl. 1991;32:219-23. doi: 10.1007/978-3-0348-7405-2_29. Agents Actions Suppl. 1991. PMID: 2069090
• IL-1 trap. Regeneron/Novartis.

  Gabay C. Gabay C. Curr Opin Investig Drugs. 2003 May;4(5):593-7. Curr Opin Investig Drugs. 2003. PMID: 12833655 Review.
• Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?

  McCarey DW, Sattar N, McInnes IB. McCarey DW, et al. Arthritis Res Ther. 2005;7(2):55-61. doi: 10.1186/ar1496. Epub 2005 Jan 21. Arthritis Res Ther. 2005. PMID: 15743490 Free PMC article. Review.